Adoptive transfer of Munc13-4–corrected EBV-specific T cells induces the regression of EBV B-cell lymphoma in NSG mice. (A) Experimental design for the xenograft NSG mouse model. The experiment was performed with PBMCs from P5 (an EBV-seropositive patient). N = 3 mice per group. (B) The dot plot represents the number of Munc13-4/CFP⁺ or CFP⁺ cells as a percentage of the CD8⁺-gated population 7 days after transduction. (C) Bioimmunoluminescence imaging using the IVIS in vivo imaging system (Xenogen; Caliper Life Sciences, Hopkinton, MA) for NSG mice bearing EBV B-cell lymphoma. EBV-T cells, EBV-specific cytotoxic T cells. (D) The time course of tumor growth. Photon emission from luciferase-positive tumor cells was quantified as the peak photons per second per cm² per steradian (p/s/cm²/sr). Error bars represent the mean ± standard error of the mean (SEM). The P value was calculated in a 2-way analysis of variance with a Bonferroni posttest. (E) The percentage of human CD3⁺ (hCD3⁺) T cells and luciferase-expressing lymphoma cells in digested tumors, as measured by flow cytometry. The mean cell count ± SD is shown. The P value was calculated in an unpaired Student t test. *P < .05; **P < .01; ***P < .001. IP, intraperitoneal; SC, subcutaneous.